Close menu




September 30th, 2020 | 11:45 CEST

BAT, Barrick Gold, Osino Resources: Supposed political risks, a burden, and an opportunity

  • Investments
Photo credits: pixabay.com

Businesses, like citizens, operate within the regulatory framework. In this way, the state guarantees peaceful coexistence. But what if the legal framework changes? It is easy for individuals to adapt to new circumstances. It can be more challenging for companies - for example, if a business model is shaken by regulatory requirements. The best example is the tobacco company BAT. Recently, the German Bundesrat cleared the way for a law that further restricts advertising for tobacco products. Even e-cigarettes, celebrated by the industry as a source of hope, will be subject to the likely ban. Cinema advertising, marketing activities, etc will also be restricted in the future.

time to read: 3 minutes | Author: Nico Popp
ISIN: CA68828L1004 , CA0679011084 , GB0002875804

Table of contents:


    BAT: Good figures fizzle out on the market

    For companies like BAT, the new laws in Germany are just another chapter in the never-ending story. But although smokers and tobacco companies have been facing headwinds for years, BAT is holding up comparatively well. In the first half of the year, the group even managed to increase its profits by more than 20%.

    The driving force continues to be e-cigarettes, which - despite political headwinds - are popular with customers. BAT is also favorably valued: the price-earnings ratio is below 10, and the dividend yield is also impressive at around 8%. Nevertheless, the share is not a high-flyer on the stock market: on a one-year horizon, despite the solid-key data, a loss of around 3% is recorded. Investors seem to find the anti-smoking policy so deterrent that they are avoiding the share despite the positive figures.

    Barrick Gold has costs under control

    The Barrick Gold share shows that political headwinds do not always have to result in falling prices. The company is still in dispute with Papua New Guinea over the resumption of production at the Porger Mine. The background is environmental damage, which the country would like to see Barrick repair. For its part, the company announces that it intends to resolve the dispute and take all necessary steps. Nevertheless, the dispute continues to smolder. In recent years, Barrick has also been involved in conflicts with authorities in other regions of the world, such as Chile, but that has not hurt the share. On a one-year horizon, Barrick climbed by almost 50%.

    Investors appreciate the share's robust sales growth and low costs. In times when gold prices are rising, this provides a comfortable cushion. In recent months there have been sales of mines that the Group considers unprofitable. Barrick primarily mines gold but also has copper on offer. Both commodities have been performing well since the pandemic, so it can be assumed that the disease will not play any role in Barrick's figures.

    Osino Resources seeks gold in Namibia

    The Osino Resources share has also benefited from the development of the past six months - since the end of March, the share price has only known one direction, and that is up. It has increased by 61% on a one-year horizon. Osino Resources is a Canadian commodities company specializing in gold exploration in Namibia. Namibia is considered one of the most stable countries in Africa with highly developed mining standards and an industry minded government. Osino Resources operates in the promising gold belt northeast of the capital Windhoek. Within twenty kilometres around the company's properties are roads, access to energy, and other essential infrastructure. By the end of 2020, the company plans to confirm and expand on promising results already achieved by drilling new wells.

    Insiders and professional investors rely on Osino Resources

    The experienced management team believes in itself and the project, this is shown by the high proportion of Osino shares in its portfolio: around 38% are in the hands of insiders or other persons associated with the company. Professional investors hold another 34%. Private investors, therefore, account for only ~28% of the company's shareholders. Many private investors still shy away from investing in Africa and see political risks.

    Osino Resources does not see such fears and emphasises the advantages of Namibia as a mining location. The country has a mining history of more than 110 years. Raw materials contribute to a large extent to the country's gross domestic product. As Namibia has been a democracy since 1990, workers and residents of mining projects have rights and can enforce them. The risk of unrest, strikes, and other complications is lower in Namibia than in many other traditional mining regions.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read